Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-03-15

FDA Approved: IRBESARTAN — Supplemental Application (Solco Healthcare U.S., LLC)

View source ↗

Summary

FDA approved a supplemental application for IRBESARTAN from Solco Healthcare U.S., LLC, indicating a labeling change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irbesartan (irbesartan)

Snippet

SUPPL AP for IRBESARTAN (IRBESARTAN)